|
Characteristic
|
Number
|
%
|
|---|
|
Age at diagnosis
| | |
|
< 50
|
290
|
35.4
|
|
> 50
|
529
|
64.6
|
|
T stage
| | |
|
T1
|
613
|
74.8
|
|
T2
|
195
|
23.8
|
|
T3
|
11
|
1.4
|
|
Number of positive nodes
| | |
|
0
|
586
|
71.6
|
|
1-3
|
219
|
26.7
|
|
> 4
|
10
|
1.2
|
|
No nodes sampled
|
4
|
0.5
|
|
Grade
| | |
|
1
|
84
|
10.3
|
|
2
|
431
|
52.6
|
|
3
|
300
|
36.6
|
|
Unknown
|
4
|
0.5
|
|
ER or PR positive
|
656
|
80.1
|
|
HER2 positive
|
109
|
13.3
|
|
LVI present
|
137
|
16.7
|
|
Hormonal therapy received
|
553
|
67.5
|
|
Chemotherapy received
|
389
|
47.5
|
|
Trastuzumab therapy received (if HER2 positive, Number = 108)
|
28
|
25.9
|
|
Margins
| | |
|
Close or positive
|
27
|
3.3
|
|
Negative
|
791
|
96.6
|
|
Unknown
|
1
|
0.1
|
|
Constructed subtype
| | |
|
HR+/HER2+
|
574
|
70
|
|
HR+HER2+
|
57
|
7
|
|
HR-/HER2+
|
51
|
6.2
|
|
HR-/HER2-
|
94
|
11.5
|
|
Unknown
|
43
|
5.3
|
- ER, estrogen receptor; HER2, human epidermal growth receptor 2; LVI, lymphovascular space invasion; PR, progesterone receptor.
